細胞名稱(chēng)

人胰腺癌細胞CFPAC1

貨物編碼

BFN60808541

產(chǎn)品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研      2類(lèi)

培養體系

DMEM高糖+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡(jiǎn)介

人胰腺癌細胞CFPAC1取自26歲男性供體。該細胞源于ATCC

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Doubling time: 30 hours (at 17th passage), 32 hours (at 74th passage) (PubMed=1692630); 45 hours (PubMed=25984343).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Proteome analysis by 2D-DE/MS.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Misspelling: CFPANC1; In CGH-DB 164-1.

基因突變

Homozygous for CFTR p.Phe508del (c.1521_1523delCTT) (PubMed=15463957; ATCC).

Heterozygous for KRAS p.Gly12Val (c.35G>T) (PubMed=11169959; PubMed=11787853; PubMed=15367885; Cosmic-CLP).

Homozygous for SMAD4 deletion (PubMed=10408907; PubMed=11169959; PubMed=11787853; PubMed=15367885).

Homozygous for TP53 p.Cys242Arg (c.724T>C) (PubMed=11169959; PubMed=11787853; PubMed=15367885; Cosmic-CLP).

HLA信息

/

STR信息

Amelogenin        X,Y

CSF1PO        10

D2S441        10,14

D2S1338        18,23

D3S1358        16

D5S818        10,11

D6S1043        20

D7S820        8,10

D8S1179        11,15

D12S391        17

D13S317        12

D16S539        9,11

D18S51        12

D19S433        13,15

D21S11        30,31.2

FGA        21,22

Penta D        11,13

Penta E        10,12

TH01        8

TPOX        8

vWA        17

參考文獻

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402(2020)